Table 4 Summary of TEAEs of special interest—incidence by time periods
Preferred term | Study treatment period | ||
|---|---|---|---|
1–8 weeks | 9–24 weeks | >24 weeks | |
# of subjects continuing treatment, n (%) | 82 (100) | 58 (100) | 23 (100) |
 Thrombocytopenia | 70 (85.4) | 42 (72.4) | 18 (78.3) |
 Nausea/vomiting | 68 (82.9) | 21 (36.2) | 5 (21.7) |
 Fatigue/asthenia | 58 (70.7) | 15 (25.9) | 5 (21.7) |
 Neutropenia/febrile neutropenia | 54 (65.9) | 34 (58.6) | 10 (43.5) |
 Hyponatremia | 52 (63.4) | 18 (31.0) | 6 (26.1) |
 Decreased appetite | 46 (56.1) | 16 (27.6) | 8 (34.8) |
 Weight decreased | 44 (53.7) | 27 (46.6) | 7 (30.4) |
 Neurotoxicity | 24 (29.3) | 7 (12.1) | 1 (4.3) |
 Diarrhea | 22 (26.8) | 7 (12.1) | 1 (4.3) |
 Pneumonia | 20 (24.4) | 7 (12.1) | 3 (13.0) |
 Vision blurred | 5 (6.1) | 2 (3.4) | 2 (8.7) |
 Cataract | 1 (1.2) | 1 (1.7) | 1 (4.3) |